A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer - Concepedia

Concepedia

Publication | Open Access

A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer

DOI Full Paper Access

87

Citations

26

References

2004

Year

Walter M. Stadler, Dingcai Cao, Nicholas J. Vogelzang, Christopher W. Ryan, Kristin Hoving, Russell A. Wright, Theodore Karrison, Everett E. Vokes

Clinical Cancer Research

Abstract

No disease modifying effects of SU5416 were detectable in this small study. Modest toxicity, an inconvenient administration schedule, and availability of other VEGFR-targeted agents support the decision to halt further evaluation of SU5416 in prostate cancer.

References

	Year	Citations

Page 1